Anavex Life Sciences Corp (AVXL)

[bas2020]

Falconer and others: Any thoughts about Axsome and its fast-tracked Ph3 drug AXS-05 (DM + BUP: Sigma-1 receptor agonist and more)?

AXS-05 is a novel, oral, investigational drug product under development for the treatment of central nervous system (CNS) disorders. AXS-05 utilizes Axsome’s technology of combining bupropion and dextromethorphan. Dextromethorphan is an NMDA receptor antagonist, sigma-1 receptor agonist, and inhibitor of the serotonin and norepinephrine transporters. Bupropion serves to increase the bioavailability of dextromethorphan, and is a norepinephrine and dopamine reuptake inhibitor, and a nicotinic acetylcholine receptor antagonist. We are initially developing AXS-05 for the treatment of the following conditions: treatment resistant depression (TRD), and agitation in patients with Alzheimer’s disease (AD). AXS-05 is an investigational drug product not approved by the FDA.

http://axsome.com/company/overview-pipeline/?

TIA!